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Ductal carcinoma in situ with distorting sclerosis on core biopsy may be predictive of
upstaging on excision
Aims: The aim of this study was to examine clinico-
pathological features of patients with core biopsy diag-
noses of ductal carcinoma in situ (DCIS) that may
predict invasion on subsequent excision, as upstaging
has significant implications regarding the need for axil-
lary staging via sentinel lymph node biopsy (SLNB).
Methods and results: We identified 186 patients with
a diagnosis of DCIS as the highest-stage lesion on
core biopsy. Pathological and clinical features were
assessed via slide and chart review, respectively.
Distorting sclerosis was defined as irregular angula-
tion of glands involved by DCIS but lacking definite
invasion according to histology and/or immunohisto-
chemical staining for myoepithelial markers.
Thirty-two of 186 (17.2%) cases had upstaging to
either microinvasive (nine) or invasive (23) ductal
carcinoma. SLNB was performed in 29 of 32 (90.6%)
cases with upstaging and in 55 of 154 (35.7%) cases
without (P < 0.0001). Upstaging was significantly asso-
ciated with the presurgical variables of radiological mass
(P = 0.009) and distorting sclerosis (P = 0.0005) and
the postsurgical feature of multifocality (P < 0.0001).
Conclusions: Sentinel lymph node biopsy is frequently
performed for patients with upstaging from DCIS on
core biopsy to microinvasive or invasive carcinoma
on excision. DCIS with distorting sclerosis without
definite invasion on core biopsy may be predictive of
upstaging. This feature may be useful in selecting
patients to undergo SLNB at the time of excision to
avoid reoperation.
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Introduction
Percutaneous core biopsies of suspicious breast lesions
have replaced excisional biopsies in many cases,
because they are generally safer, more cost-effective,
and less emotionally and physically disfiguring.1
However, despite the advantages of minimally inva-
sive biopsies, core biopsy is inherently limited in the
amount of tissue obtained for pathological evaluation,
resulting in the possibility of missing invasive disease
and sampling only in-situ disease. On average, 6.6%
and 22% of women diagnosed with ductal carcinoma
in situ (DCIS) on core biopsy are upstaged to microin-
vasive and invasive ductal carcinoma, respectively,
on subsequent excision, with an overall range of
upstaging of 8–47%.2–18 Several studies have investi-
gated clinicopathological features in patients with
core biopsy diagnoses of DCIS, in an attempt to pre-
dict invasion on subsequent excision, as this has sig-
nificant implications regarding the need for axillary
staging via sentinel lymph node biopsy (SLNB). Cur-
rently, SLNB is the standard practice in patients with
invasive disease and clinically negative axillary lymph
nodes. However, the use of SLNB in patients with
DCIS on core biopsy is controversial. The American
Society of Clinical Oncology recently published clini-
cal practice guidelines on the use of SLNB for patients
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with early-stage breast cancer.19 With regard to DCIS
diagnosed by core biopsy, the panel recommends that
women should be offered SLNB in the following cir-
cumstances: when a mastectomy will be the mode of
definitive excision, as SLNB will not be technically
feasible afterwards; when a mass highly suspicious
for invasive carcinoma is either palpable or noted
radiologically; or when the area of DCIS is
≥50 mm.19 Because reoperation causes additional
physical and emotional stress for the patient, is tech-
nically more challenging, and imposes additional
financial burdens on the patient and healthcare sys-
tem, SLNB should be performed at the time of exci-
sion if indicated. However, SLNB should not be
performed in all cases of pure DCIS, owing to the
low, but real, probability of complications, including
allergic reaction to the dye used, lymphoedema, infec-
tion, seroma, longer duration of anaesthesia, and
injury to regional nerves, resulting in sensory and
motor deficits.19 Ideally, patients showing features
suggestive of invasive disease should be selected to
undergo SLNB at the time of excision. To date, few
features have consistently surfaced as strong predic-
tors of upstaging on excision. The clinicopathological
features that are most commonly associated with
upstaging to invasive disease include the presence of
a palpable or radiological mass, and core biopsy
pathology of high nuclear grade DCIS with come-
donecrosis.3,5,6,13,15,17,18 In this study, we evaluated
a combination of clinical and pathological features in
core biopsies with DCIS in an attempt to determine
novel features that may predict upstaging to invasive
carcinoma on excision.
Materials and methods
After Institutional Review Board approval, a retro-
spective search (2006–2011) of the University of
Michigan pathology electronic database identified
188 female patients with a diagnosis of DCIS as the
highest-stage lesion on breast core biopsy. Only
patients who underwent subsequent definitive exci-
sion (breast conservation therapy or mastectomy) at
the University of Michigan were included. Core biop-
sies were either ultrasound-guided or stereotactic-
guided vacuum-assisted core needle biopsies. Clinical
characteristics including patient age, the presence of
a radiological mass and/or radiological calcifications,
biopsy method, number of sites biopsied, number of
biopsy samples per site and timing of SLNB were
obtained from patient electronic medical records.
Diagnosis, size, multifocality (defined as two or more
discrete foci at least 20 mm apart), the presence of
calcifications in DCIS and the pathological status of
sentinel lymph nodes [negative, micrometastasis
(≤2 mm) and macrometastasis (>2 mm)] were
obtained from pathology reports. All original hae-
matoxylin and eosin-stained slides and available
immunohistochemical (IHC) stains performed at the
time of diagnosis were re-reviewed by two patholo-
gists (J.P. and J.J.) with experience in breast pathol-
ogy. Two cases with microinvasion confirmed by
myoepithelial IHC staining were excluded. Histopath-
ological features, including linear involvement of
core biopsy, highest nuclear grade, presence of cen-
tral necrosis, primary architectural pattern, cancer-
ization of lobules, degree of periductal chronic
inflammation, expression of oestrogen receptor (ER)
and progesterone receptor (PR), presence of periduc-
tal fibrosis, and presence of distorting sclerosis, were
included in the analysis. Focal was defined as
involvement of one to three ducts, and extensive as
involvement of more than three ducts. Distorting
periductal sclerosis was defined as periglandular des-
moplasia or fibrosis resulting in irregular angulation
of glands involved by DCIS (Figure 1A–C), whereas
periductal fibrosis was defined as a concentric rim of
fibrosis encircling the duct without distortion of the
lumen. Distorting sclerosis was defined as ‘severe’
when the distortion of the glands was marked and
concerning for or difficult to discern from microinva-
sion via histological examination alone. Nuclear
grade was determined according to consensus com-
mittee guidelines.20 ER and PR immunostains were
reviewed and categorized as positive (>10% staining),
weak (1–10% staining), or negative (<1% staining).
The primary architectural pattern of DCIS was cate-
gorized as solid, cribriform, comedo, micropapillary,
papillary, or other.
All cases showing severe distorting sclerosis were
further evaluated for invasion by IHC staining for
myoepithelial markers (muscle-specific actin, clone
HHF35, and p63, clone 4A4; Ventana, Tucson, AZ,
USA) if not performed at the time of diagnosis. All
cases showed intact myoepithelium, confirming the
morphological interpretation of DCIS (Figure 1D).
Figure 1. A–G, Ductal carcinoma in situ (DCIS) with distorting sclerosis, with architectural distortion and irregular angulation of glands,
and with ‘severe’ distortion in (E)–(G) (haematoxylin and eosin). H, Muscle-specific actin immunohistochemical staining highlights the myo-
epithelial cells in (G), supporting the diagnosis of DCIS (IHC).
© 2014 John Wiley & Sons Ltd, Histopathology, 66, 577–586.
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S T A T I S T I C A L A N A L Y S I S
Patients with DCIS as the highest-stage lesion
(n = 154) and upstaging to microinvasive or invasive
carcinoma (n = 32) were compared for pathological
and clinical features. Categorical variables were tested
between groups by the use of Fisher’s exact or chi-
square tests. Continuous variables were tested with
t-tests or Wilcoxon rank tests as appropriate, accord-
ing to the distribution. Logistic models were used to
determine associations between covariates and
upstaging. SAS 9.4 (SAS Institute, Cary, NC, USA)
was used for all statistical analyses. A P-value of
<0.05 was considered to be significant.
Results
C L I N I C O P A T H O L O G I C A L F E A T U R E S C O R R E L A T I N G
W I T H U P S T A G I N G
Of the 186 patients included in this study, 69 (37.1%)
underwent mastectomy and 117 (62.9%) underwent
lumpectomy for definitive surgical treatment.
Ductal carcinoma in situ remained the highest-
stage lesion on excision in 154 of the cases (82.8%);
these included 13 cases with no residual neoplasm
that were smaller in size (mean 4 mm, range 0.1–
8 mm) and more frequently low grade (6/13; 46.1%)
and ER-positive (11/13; 84.6%).
Thirty-two patients (17.2%) were upstaged to either
microinvasive (nine) or invasive (23) ductal carcinoma
on excision, with a mean lesion size of 5 mm (range
<1–15 mm). On univariable analysis, the presence of a
radiological mass (P = 0.0004), periductal chronic
inflammation (P = 0.03) and distorting periductal scle-
rosis (P <0.0001) were significantly associated with
upstaging to microinvasive or invasive ductal carci-
noma on excision (Table 1). However, on multivariable
analysis, only the presence of a radiological mass
(P = 0.009) and distorting sclerosis (P = 0.0005)
remained significantly associated with upstaging.
Comparison of the features of the excision speci-
mens between the two groups demonstrated that
multifocal DCIS was significantly associated with
upstaging to invasive disease (P < 0.0001) (Table 2).
C A S E S W I T H D I S T O R T I N G S C L E R O S I S
All cases of DCIS with distorting sclerosis evaluated
by IHC staining for myoepithelial markers had posi-
tive myoepithelial staining that was patchy in nature
(Figure 1D), except for two cases that were were
noted to have strong, diffuse staining (Figure 2A, B).
Review of the subsequent excision specimens in these
two cases confirmed DCIS involvement of sclerosing
adenosis.
None of the patients with distorting sclerosis had
undergone previous biopsy in the same breast quad-
rant, excluding sclerosis resulting from reparative
change.
Distorting sclerosis was associated with high grade,
comedonecrosis, extensive cancerization of lobules,
extensive periductal chronic inflammation, and ER/
PR negativity (Table 3). Distorting sclerosis was not
associated with the other clinicopathological features
examined in this study. It is of note that there was
no significant difference regarding the presence of a
mass lesion, which was seen in 12 of 50 (24%) of
cases with and 25 of 136 (18.4%) cases without dis-
torting sclerosis.
Mass lesion was more frequently seen in cases with
distorting sclerosis with upstaging on excision (8/21;
38.1%) than in those without (4/29; 13.8%). Of the
21 patients with distorting sclerosis that had upstag-
ing, the majority underwent stereotactic core biopsy
(19/21; 90.5%), the rate being similar to the overall
rate (Table 1).
S L N B S
Sentinel lymph node biopsy was performed in 84 of
186 patients (45.2%), and was more frequently per-
formed in patients who had undergone mastectomy
(56/69; 81.2%) than in those who had undergone
breast-conserving therapy (28/117; 23.9%)
(P < 0.0001).
Of the patients who underwent SLNB, 83 of 84
(98.8%) had negative sentinel lymph nodes, and one
of 84 (1.2%) had a micrometastasis. The single
patient with a micrometastasis was a 43-year-old
woman with a 150-mm span of suspicious microcal-
cifications and associated density on mammography.
Core biopsy showed high-grade DCIS with comedone-
crosis and microcalcifications that was ER-positive
(97%) and PR-positive (15%). Distorting sclerosis was
also present. Simple mastectomy revealed a 15-mm
focus of invasive ductal carcinoma and extensive
DCIS. The patient had micrometastatic carcinoma in
one of eight sentinel lymph nodes, and later surgery
for axillary lymph node dissection revealed 22 addi-
tional lymph nodes that were negative for carcinoma.
Reoperation was performed for SLNB in 22 of 84
patients (26.2%): 11 with pure DCIS, and 11 with
upstaging on excision. Eight of the 11 (72.7%)
patients with upstaging had distorting sclerosis on
core biopsy.
© 2014 John Wiley & Sons Ltd, Histopathology, 66, 577–586.
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Table 1. Preoperative clinicopathological features in patients with ductal carcinoma in situ (DCIS) as the final pathological
lesion and in patients upstaged to microinvasive or invasive carcinoma on final excision
Final pathological diagnosis
P-valueDCIS (n = 154)
Microinvasive or invasive
carcinoma (n = 32)
Patient age (years), mean (range) 57.7 (32.0–87.9) 55.9 (43.1–79.2) 0.42
Radiological mass, no. (%) 23 (14.9) 14 (43.8) 0.0004
Radiologic calcifications (%) 140 (90.9) 31 (96.9) 0.47
Biopsy procedure, no. (%)
Stereotactic 138 (89.6) 29 (90.6) 0.30
8-gauge 70 (45.2) 19 (59.4)
11-gauge 68 (44.2) 10 (31.2)
Ultrasound-guided (14 gauge) 15 (9.7) 2 (6.3)
MRI-guided 1 (0.7) 0 (0)
Office (clinician-performed) 0 (0) 1 (3.1)
Median number of sites biopsied (range) 1 (1–3) 1 (1–2) 0.11
Median number of cores submitted
per site (range)
6 (1–19) 6 (4–12) 0.29
Mean linear extent of core involvement
(mm) (range)
6 (1–17) 7 (2–17) 0.08
Nuclear grade, no. (%)
Low 20 (13) 1 (3.1) 0.16
Intermediate 52 (33.8) 9 (28.1)
High 82 (53.2) 22 (28.8)
Comedonecrosis, no. (%)
None 55 (35.7) 8 (25) 0.36
Focal 50 (32.5) 10 (31.3)
Extensive 41 (26.6) 14 (43.7)
Primary architectural pattern, no. (%)
Solid 70 (45.5) 13 (40.6) 0.65
Cribriform 27 (17.5) 4 (12.5)
Comedo 36 (23.4) 11 (34.4)
Micropapillary 6 (3.9) 0 (0)
Papillary 12 (7.8) 3 (9.4)
Other 3 (1.9) 1 (3.1)
© 2014 John Wiley & Sons Ltd, Histopathology, 66, 577–586.
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Discussion
The present study evaluated a combination of clinical
and pathological features in patients diagnosed with
DCIS on core biopsy. Although pure DCIS theoreti-
cally has no metastatic potential, patients are not
infrequently upstaged to microinvasive or invasive
carcinoma, owing to incomplete sampling of lesions
on core biopsy. Because invasive disease necessitates
axillary staging, many patients must undergo a sec-
ond operation unless staging was performed at the
time of excision. Axillary staging at the time of exci-
sion for all cases of DCIS is not a viable alternative,
owing to the low risk of axillary lymph node involve-
ment and potential adverse effects associated with the
procedure. Thus, clinicopathological features allowing
clinicians to determine which patients are at risk for
upstaging on excision would be immensely helpful to
Table 1. (Continued)
Final pathological diagnosis
P-valueDCIS (n = 154)
Microinvasive or invasive
carcinoma (n = 32)
Cancerization of lobules, no. (%)
None 68 (44.2) 10 (31.3) 0.24
Focal 45 (29.2) 9 (28.1)
Extensive 41 (26.6) 13 (40.6)
Periductal inflammation, no. (%)
None 56 (36.4) 10 (31.2) 0.03
Focal 56 (36.4) 6 (18.8)
Extensive 42 (27.2) 16 (50)
Oestrogen receptor expression, no. (%)
Negative (<1%) 32 (20.8) 6 (18.7) 0.10
Weak (1–10%) 3 (2) 3 (9.4)
Positive (>10%) 119 (77.3) 23 (71.9)
Progesterone receptor expression, no. (%)
Negative (<1%) 45 (29.2) 12 (37.5) 0.24
Weak (1–10%) 11 (7.1) 0 (0)
Positive (>10%) 98 (63.6) 20 (62.5)
Periductal fibrosis, no. (%)
None 19 (12.3) 2 (6.3) 0.25
Focal 58 (37.7) 9 (28.1)
Extensive 77 (50) 13 (40.6)
Distorting sclerosis, no. (%)
None 125 (81.2) 11 (34.4) <0.0001
Focal 24 (15.6) 17 (53.1)
Severe 5 (3.2) 4 (12.5)
MRI, Magnetic resonance imaging.
© 2014 John Wiley & Sons Ltd, Histopathology, 66, 577–586.
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minimize the unnecessary use and maximize the util-
ity of SLNB in appropriate patients.
In our study, the rate of upstaging to microinvasive
or invasive carcinoma was 17.2%, which is consistent
with the range of 8–47% reported in the literature, and
comparable with the 25.9% reported in a meta-
analysis of 7350 patients diagnosed with DCIS.2–18,21
Multivariable analysis of clinicopathological features
demonstrated that the preoperative features of radio-
logical mass (P = 0.009) and distorting sclerosis on
biopsy (P = 0.0005) were significantly associated with
upstaging to microinvasive or invasive carcinoma.
Similar to our findings, several studies have found
an association between the presence of a mass on
imaging and/or clinical examination and upstaging
on excision.2,3,5–7,9,10,12,13,16–18 When lesions were
stratified by size, a meta-analysis found that lesions
>20 mm were strongly associated with underestima-
tion of invasive carcinoma on biopsy.21
To our knowledge, this is the first study to evaluate
the significance of distorting sclerosis and upstaging
of DCIS to invasive carcinoma on definitive excision.
We defined distorting sclerosis as desmoplasia or
dense fibrosis in surrounding stroma causing irregu-
lar angulation of glands involved by DCIS. This is in
contrast to periductal fibrosis, which we considered to
be encasement of ducts by concentric non-distorting
fibrosis. All cases with distorting sclerosis lacked
obvious invasion according to morphology; however,
the cases with severe distorting sclerosis showed such
distortion that immunohistochemical staining for
myoepithelial markers was performed to verify the
in-situ nature. Chivukula et al.22 examined 35 cases
of high-grade DCIS with thick periductal scarring and
variable lymphoid infiltrates. They coined the phe-
nomenon ‘regressive changes’, akin to the changes
seen in regressive changes of malignant melanoma.
They outlined several stages of regression: a dense
periductal lymphocytic infiltrate, followed by increas-
ing periductal fibrosis, and eventual obliteration of
neoplastic cells and the duct lumen with attenuation
of the inflammatory response. In their study of high-
grade DCIS with and without regressive changes,
they noted a higher propensity for upstaging to inva-
sive carcinoma on excision in the group with regres-
sive changes (20% versus 4%). Although cases of
distorting sclerosis showed intact myoepithelial
Table 2. Postoperative clinicopathological features in
patients with ductal carcinoma in situ (DCIS) as the final
pathological lesion and in patients upstaged to microinva-
sive or invasive carcinoma on final excision
Final pathological
diagnosis
P-value
DCIS
(n = 154)
Microinvasive
or invasive
carcinoma
(n = 32)
Multifocal disease, no. (%)
None 95 (61.7) 5 (15.6) <0.0001
DCIS 59 (38.3) 23 (71.9)
Invasive  DCIS 0 (0) 4 (12.5)
Calcifications in
DCIS, no. (%)
142 (92.2) 31 (96.9) 0.70
Final surgery, no. (%)
Lumpectomy 101 (65.6) 16 (50) 0.10
Mastectomy 53 (34.4) 16 (50)
A
B
Figure 2. A, High-grade apocrine ductal carcinoma in situ involv-
ing sclerosing adenosis (haematoxylin and eosin). B, Corresponding
strong, positive muscle-specific actin immunohistochemical staining
highlighting myoepithelium throughout.
© 2014 John Wiley & Sons Ltd, Histopathology, 66, 577–586.
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staining, the staining was patchy in most cases, like
that described by Chivukula et al.22 This raises the
possibility that distorting sclerosis and regressive
changes may have a related aetiology. Chivukula
et al. proposed that the increased rate of invasive
carcinoma may be attributable to a decrease in the
density of the myoepithelial layer, allowing neoplastic
cells to easily cross the unprotected basement mem-
brane. Like the cases with regressive change, cases
with distorting sclerosis were more frequently high
grade and had prominent periductal chronic inflam-
mation.22
Sclerosing lesions, such as sclerosing adenosis and
radial scars, are associated with a 1.5-fold to two-fold
increase in the risk of developing invasive breast carci-
noma, which is similar to the level of risk associated
with other proliferative lesions without atypia.23–25
Yoshida et al.26 showed that patients with sclerosing
adenosis involved by DCIS had a significantly higher
rate of synchronous or metachronous bilateral inva-
sive breast carcinoma than patients with DCIS in the
absence of sclerosing adenosis. These findings raise the
possibility that an underlying sclerosing lesion may
accelerate the progression from DCIS to invasive carci-
noma. In our study, severe distorting sclerosis on core
biopsy represented DCIS involving sclerosing adenosis
in two cases. These cases showed strong myoepithelial
immunostaining, which aided significantly in ruling
out invasive carcinoma and was easily distinguished
from the pattern of reduced, patchy myoepithelial
staining in distorting sclerosis. The paucity of involve-
ment by sclerosing lesions in our cohort suggests that
the association between distorting sclerosis and inva-
sive carcinoma is probably not attributable to risk
caused by a background sclerosing lesion, but is actu-
ally a real, independent risk factor for invasive disease.
Severity of periductal chronic inflammation was a
significant predictor of upstaging to invasive carci-
noma on univariable analysis (P = 0.03) but not on
multivariable analysis. This association was most influ-
enced by a skew towards more extensive chronic
inflammation in patients with upstaging on excision.
The interface between the immune system and cancer
and how their interaction affects disease progression
has become an important area of research interest.
CD4+/CD25+ regulatory T cells (TRs), which typically
suppress T-cell proliferation and cytokine production,
are found in increased numbers in autoimmune disease
and numerous cancers, including breast cancer, and
are considered to be markers of poor clinical outcome.
Both Bates et al. and Lal et al.27,28 showed that TR
numbers progressively increase from benign breast tis-
sue to DCIS to invasive carcinoma, and serve as a mar-
ker of breast cancer progression. Our findings of the
association between extensive periductal inflammation
on core biopsy and subsequent upstaging on excision
supports the current hypothesis that an increased
number of TRs results in suppression of normal host
immune defences, facilitating tumour progression.
In our cohort, SLNB was performed at the time of
excision in 18 of 32 (56.3%) patients upstaged to
microinvasive or invasive carcinoma according to
Table 3. Histological features associated with ductal carci-
noma in situ with distorting sclerosis
No distorting
sclerosis
(n = 136)
Distorting
sclerosis
(n = 50) P-value
Nuclear grade, no. (%)
Low 21 (15.5) 0 (0) <0.0001
Intermediate 55 (40.4) 6 (12)
High 60 (44.1) 44 (88)
Comedonecrosis, no. (%)
None 57 (41.9) 6 (12) <0.0001
Focal 47 (34.6) 13 (26)
Extensive 32 (23.5) 31 (62)
Cancerization of lobules, no. (%)
None 69 (50.7) 9 (18) 0.0001
Focal 37 (27.2) 17 (34)
Extensive 30 (22.1) 24 (48)
Periductal inflammation, no. (%)
None 61 (44.9) 5 (10) <0.0001
Focal 48 (35.3) 14 (28)
Extensive 27 (19.8) 31 (62)
Oestrogen receptor expression, no. (%)
Negative (<1%) 20 (14.7) 18 (36) 0.0002
Weak (1–10%) 2 (1.5) 4 (8)
Positive (>10%) 114 (83.8) 28 (56)
Progesterone receptor expression, no. (%)
Negative (<1%) 30 (22.1) 26 (52) 0.0004
Weak (1–10%) 9 (6.6) 2 (4)
Positive (>10%) 97 (71.3) 22 (44)
© 2014 John Wiley & Sons Ltd, Histopathology, 66, 577–586.
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final pathology findings, whereas reoperation was
performed in 11 of the 14 remaining patients for
whom SLNB was recommended. Among patients with
pure DCIS as a final diagnosis, 55 of 154 (35.7%)
had unnecessary SLNBs. If every patient in our study
cohort who either presented with a radiological mass
or showed DCIS with distorting sclerosis on core
biopsy had undergone SLNB at the time of excision,
27 of the 32 (84.3%) with the final diagnosis of mi-
croinvasive or invasive carcinoma would have under-
gone concurrent SLNB. As compared with the
current clinical practice at our institution, 11 addi-
tional patients with a final diagnosis of microinvasive
or invasive carcinoma would have undergone SLNB
at excision instead of requiring reoperation, and
seven patients with pure DCIS would have been
spared an unnecessary procedure.
Distorting sclerosis is a novel feature in DCIS that
appears to be predictive of upstaging to microinvasive
or invasive cancer on excision. Distorting sclerosis
may be related to ‘regressive change’, and shows a
similar intact but reduced myoepithelial density,
which was previously theorized to allow for greater
ease of invasion into the stroma. IHC staining for
myoepithelial markers may be helpful in differentiat-
ing DCIS with distorting sclerosis from true microin-
vasion and from DCIS involving sclerosing lesions.
However, identification of DCIS with distorting sclero-
sis via routine histological examination may often be
sufficient. When it is present, a statement may be
included in the pathology report to alert the surgeon
that higher-stage disease may be present and that
SLNB should be considered at the time of excision.
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